Meeting
2022 ASCO Genitourinary Cancers Symposium
Transcriptomic discriminators of response to apalutamide in patients with prostate cancer (PC) on active surveillance (AS).
Authors
Michael Thomas Schweizer
University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA
Michael Thomas Schweizer , Roman Gulati , Yang Liu , Alexander K. Hakansson , Elai Davicioni , Lawrence True , William J. Ellis , George Schade , Robert B. Montgomery , Sonia Wadhera , Katie Nega , Kenneth J. Pienta , Peter Nelson , Jonathan L. Wright , Daniel W. Lin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Clinical Trial Registration Number
NCT02721979
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 267)
DOI
10.1200/JCO.2022.40.6_suppl.267
Abstract #
267
Poster Bd #
L11
Abstract Disclosures
Similar Posters
First Author: Emma Reilly
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Exploration of the cGAS-STING pathway in prostate cancer.
First Author: Emma Reilly
Poster
2024 ASCO Annual Meeting
Dissecting the significance of ACP1 gene alterations in prostate cancer (PCa).
First Author: Nour Abdallah
Poster
2024 ASCO Genitourinary Cancers Symposium
EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors.
First Author: Guillaume Grisay